Poly Medicure Q1 FY27 results: PAT at ₹85.27 cr

Board meeting on August 7, 2026: what was approved

Poly Medicure Limited’s Board of Directors met on August 7, 2026 to consider financial and corporate matters. The company said the board approved its unaudited financial results for the first quarter ended June 30, 2026. The approval covered both standalone and consolidated results. The disclosure also refers to detailed review reports being attached with the filing. Alongside financial approvals, the board meeting included decisions linked to employee stock incentives and statutory compliance items. The company also recorded a key managerial change through a resignation that will take effect a few days after the meeting.

Unaudited Q1 results for the quarter ended June 30, 2026

For the quarter ended June 30, 2026, Poly Medicure reported standalone profit after tax (PAT) of ₹8,062.17 lacs, which is ₹80.6217 crore. On a consolidated basis, profit after tax was ₹8,527.43 lacs, or ₹85.2743 crore. The company also disclosed total comprehensive income for the quarter. Standalone total comprehensive income was ₹8,705.10 lacs (₹87.0510 crore), while consolidated total comprehensive income was ₹8,523.11 lacs (₹85.2311 crore). These numbers were part of the unaudited quarterly results approved by the board.

Standalone and consolidated EPS disclosed

Along with profitability, the company disclosed earnings per share (EPS) for the quarter. Basic EPS for the period stood at ₹8.68 on a standalone basis. On a consolidated basis, the basic EPS was ₹8.49. The disclosure does not include additional per-share metrics beyond these basic EPS figures. The company’s results were approved as unaudited numbers for Q1.

ESOP Scheme 2020: stock option grant approved

The Nomination and Remuneration Committee (NRC) approved actions related to the company’s employee stock option programme. Under the Poly Medicure Limited Employee Stock Option Scheme 2020, the NRC approved the grant of 1,476 stock options to eligible employees. The disclosure positions this as part of employee incentives under the existing ESOP framework. No additional terms for vesting, exercise price, or timelines were provided in the text shared.

ESOP Scheme 2020: equity shares allotted on option exercise

In addition to granting options, the NRC also approved the allotment of shares to employees who exercised their options. The committee approved the allotment of 1,975 equity shares. Each share has a face value of ₹5, as disclosed. Following this allotment, the paid-up equity share capital increased to ₹50,68,07,325, representing 10,13,61,465 equity shares. This item is a key corporate action outcome from the board process, reflecting the ongoing impact of ESOP exercises on the company’s equity base.

Paid-up capital update: what changed after the ESOP allotment

The share allotment figure is small relative to the overall equity base, but it formally increases the paid-up capital and number of equity shares outstanding. The disclosure states the updated paid-up equity share capital as ₹50,68,07,325 and the updated count as 10,13,61,465 equity shares. The face value of each share was disclosed as ₹5. The filing does not provide a before-and-after equity count in the excerpt, but it clearly states the updated post-allotment paid-up capital position.

Cost auditor re-appointed for FY2026-27

The board also dealt with statutory compliance matters. Poly Medicure re-appointed M/s Jai Prakash & Company as cost auditors for the financial year 2026-27. The disclosure does not mention the audit fee or any change in scope. Cost auditor appointments are typically part of routine governance processes, and the company has disclosed the firm name and the financial year for which the appointment applies.

Resignation of Deputy Company Secretary and Compliance Officer

The company noted a resignation during the board meeting outcomes. Mr. Ravi Prakash tendered his resignation as Deputy Company Secretary and Compliance Officer. The resignation is effective August 10, 2026. The company stated the reason as pursuing other career opportunities. This change falls within corporate governance disclosures that investors track because the role is linked to compliance and exchange-facing responsibilities.

Key numbers and actions at a glance

Board meeting history shown in the disclosure

The provided text also lists earlier board meetings as context. These include meetings held for audited results and dividend decisions, as well as quarterly results approvals. While the excerpt does not provide outcomes for each date in detail, it offers a schedule-style view of recent meetings. This history is useful for tracking the company’s regular financial reporting cadence through the year.

Market context in the text: price move referenced

The excerpt also includes a market data line showing “-54.50 (-3.15%)” and a timestamp “As on 03 Jul, 2026 | 15:58”. This appears as a separate market snapshot in the content provided. The board meeting and quarterly approvals were dated later, on August 7, 2026, so the market data line should be read as a reference point included in the source text rather than a direct reaction to the August meeting outcome.

Why this update matters for investors

The Q1 approval provides the latest official profitability and per-share earnings data for the quarter ended June 30, 2026, on both standalone and consolidated bases. The ESOP-related approvals show continued usage of the Employee Stock Option Scheme 2020, including both fresh option grants and share allotment on exercise. The paid-up capital update provides a clean, updated equity share count that investors often use when tracking EPS and valuation metrics. The cost auditor re-appointment and compliance officer resignation are governance items that are typically monitored for continuity and compliance readiness. The next steps will likely include routine follow-through actions such as filings related to the approved financials and any transition steps linked to the compliance role change effective August 10, 2026.